Form D · Biotechnology
SOLENO THERAPEUTICS INC
Redwood City, CA · CIK 0001484565
Offering snapshot reported Oct 4, 2023 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 4, 2023 | Initial | $59,988,250 | No comparison | 14 | SEC filing |
| Dec 22, 2017 | Initial | $15,000,006 | No comparison | 16 | SEC filing |
| Feb 8, 2017 | Initial | $602,083 | No comparison | 1 | SEC filing |
| Jul 6, 2016 | Initial | $3,151,000 | No comparison | 3 | SEC filing |
| Oct 22, 2015 | Initial | $4,555,000 | No comparison | 3 | SEC filing |
| Oct 21, 2015 | Initial | $1,434,194 | No comparison | 1 | SEC filing |
| Mar 11, 2015 | Initial | $3,684,438 | No comparison | 8 | SEC filing |
| Aug 13, 2012 | Amendment | $5,017,396 | $3,124,194vs Jan 25, 2012 | 17 | SEC filing |
| Jan 25, 2012 | Initial | $1,893,202 | No comparison | 17 | SEC filing |
| Nov 19, 2010 | Initial | $1,892,464 | No comparison | 16 | SEC filing |
| Mar 19, 2010 | Amendment | $3,309,227 | $212,013vs Feb 24, 2010 | 28 | SEC filing |
| Feb 24, 2010 | Initial | $3,097,214 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.6M
- Finders' fees
- $0
- Form D file number
- 021-493753
Source: Form D, filed Oct 4, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William James Alexander | Director |
| Anish Bhatnagar | Director, Executive |
| Stuart Collinson | Director |
| Graham K. Crooke | Director |
| Gary Crooke | Director |
| Rajen Dalal | Director |
| Steinar Engelsen | Director |
| Edgar G. Engleman | Director |
| William Harris | Director |
| Stephen N. Kirnon | Director |
| James Mackaness | Executive |
| Ernest Mario | Director |
| Gwen Melincoff | Director |
| David D. O'toole | Executive |
| Matthew Pauls | Director |
| Gina Phelps | Executive |
| Mahendra Shah | Director |
| Andrew Sinclair | Director |
| Birgitte Volck | Director |
| Jonathan D. Wolter | Executive |
| Anthony Wondka | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
203 Redwood Shores Parkway Suite 500
Redwood City, CA, 94065
Redwood City, CA, 94065